Pancreatic Cancer Research

ResearcherUniversity of Wisconsin SystemActive in the last 2 years

Douglas B. Evans

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5708-467X; OpenAlex author ID A5076270097. Sources: ClinicalTrials.gov.

Their work

Papers
89 (first author 14, last author 6)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
187
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 4 papers · 2012: 3 papers · 2013: 4 papers · 2014: 9 papers · 2015: 10 papers · 2016: 8 papers · 2017: 5 papers · 2018: 5 papers · 2019: 4 papers · 2020: 9 papers · 2021: 11 papers · 2022: 2 papers · 2023: 5 papers · 2024: 3 papers · 2025: 3 papers · 2026: 4 papers

Papers 50 of 89

  1. Limitations of GATA6 and CK5 as surrogate markers for molecular subtyping in pancreatic cancer. Co-author DOI 10.1016/j.hpb.2026.08.001↗
  2. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  3. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  4. The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection. Co-author DOI 10.3390/cancers18203376↗
  5. Local Disease Control in Patients With Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2025.0156↗
  6. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  7. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  8. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  9. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  10. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗
  11. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. First author DOI 10.1001/jamaoncol.2022.6138↗
  12. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  13. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  14. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Res… Co-author DOI 10.1245/s10434-022-12742-3↗
  15. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  16. Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. First author DOI 10.1002/jso.26756↗
  17. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  18. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. First author DOI 10.1002/jso.26395↗
  19. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  20. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Co-author DOI 10.1016/j.amjsurg.2020.12.001↗
  21. Health Care Disparities and the Future of Pancreatic Cancer Care. First author DOI 10.1016/j.soc.2021.06.012↗
  22. Updates on the Management of Pancreatic Cancer. First author DOI 10.1016/j.soc.2021.07.001↗
  23. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.06.038↗
  24. Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1016/j.surg.2020.07.024↗
  25. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  26. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  27. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  28. Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. Co-author DOI 10.3389/fonc.2021.606820↗
  29. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Co-author DOI 10.1007/s11605-019-04423-6↗
  30. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.anndiagpath.2020.151485↗
  31. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  32. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  33. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000003049↗
  34. The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505. Co-author DOI 10.1097/sla.0000000000004131↗
  35. Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. First author DOI 10.21037/hbsn.2019.11.26↗
  36. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  37. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  38. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  39. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  40. Goals of Treatment Sequencing for Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07738-5↗
  41. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  42. Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Co-author DOI 10.1007/s00261-017-1404-0↗
  43. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000002957↗
  44. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. Co-author DOI 10.1186/s12885-018-4238-4↗
  45. What Makes a Pancreatic Cancer Resectable? Co-author DOI 10.1200/edbk_200861↗
  46. Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions. Co-author DOI 10.1371/journal.pone.0199909↗
  47. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  48. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3319-4↗
  49. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  50. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Co-author DOI 10.1016/j.prro.2017.06.013↗

Trials 2

  1. Preop Chemoradiation Resectable Pancreas Principal investigator NCT00336648↗
  2. Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas Principal investigator NCT00038701↗

Closest collaborators

The 25 strongest of 187 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susan Tsai · 61 shared papers, 2012–2026 · strength 6.86
  2. William Adrian Hall · 27 shared papers, 2017–2026 · strength 4.15
  3. Kathleen K. Christians · 40 shared papers, 2013–2026 · strength 3.97
  4. Bradley A. Erickson · 35 shared papers, 2014–2025 · strength 3.62
  5. Mohammed Aldakkak · 25 shared papers, 2015–2026 · strength 3.25
  6. Ben George · 30 shared papers, 2014–2024 · strength 2.80
  7. Mandana Kamgar · 16 shared papers, 2019–2026 · strength 2.77
  8. Callisia Nathelee Clarke · 14 shared papers, 2017–2025 · strength 1.77
  9. Kulwinder S. Dua · 11 shared papers, 2012–2025 · strength 1.20
  10. Thomas B. McFall · 5 shared papers, 2024–2026 · strength 1.10
  11. Parag P. Tolat · 14 shared papers, 2012–2023 · strength 0.99
  12. Ashley N. Krepline · 11 shared papers, 2014–2021 · strength 0.88
  13. Yongwoo David Seo · 3 shared papers, 2026 · strength 0.77
  14. Razelle Kurzrock · 4 shared papers, 2024–2026 · strength 0.74
  15. Beth E. Erickson · 4 shared papers, 2021–2026 · strength 0.69
  16. Sam Z. Thalji · 4 shared papers, 2023–2026 · strength 0.69
  17. Naveen M. Kulkarni · 6 shared papers, 2018–2023 · strength 0.68
  18. Ben George · 3 shared papers, 2024–2026 · strength 0.59
  19. Chad A. Barnes · 6 shared papers, 2017–2020 · strength 0.53
  20. Saryn Doucette · 2 shared papers, 2023–2026 · strength 0.45
  21. Rebecca Y. Kim · 3 shared papers, 2020–2021 · strength 0.43
  22. Jason B. Fleming · 10 shared papers, 2011–2021 · strength 0.42
  23. Nikki K. Lytle · 2 shared papers, 2026 · strength 0.41
  24. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
  25. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.